New aporphinoid 5-HT2A and α1A antagonists via structural manipulations of nantenine.

[1]  Bo Gao,et al.  Further SAR study on 11-O-substituted aporphine analogues: identification of highly potent dopamine D3 receptor ligands. , 2011, Bioorganic & medicinal chemistry.

[2]  W. Harding,et al.  Nantenine as an acetylcholinesterase inhibitor: SAR, enzyme kinetics and molecular modeling investigations , 2011, Journal of enzyme inhibition and medicinal chemistry.

[3]  S. Bhakta,et al.  Anti-tubercular screening of natural products from Colombian plants: 3-methoxynordomesticine, an inhibitor of MurE ligase of Mycobacterium tuberculosis. , 2010, The Journal of antimicrobial chemotherapy.

[4]  J. Brubacher,et al.  Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review. , 2010, CJEM.

[5]  W. Harding,et al.  Affinity of aporphines for the human 5-HT2A receptor: insights from homology modeling and molecular docking studies. , 2010, Bioorganic & medicinal chemistry.

[6]  Xuechu Zhen,et al.  Synthesis of dihydrofuroaporphine derivatives: identification of a potent and selective serotonin 5-HT 1A receptor agonist. , 2010, Journal of medicinal chemistry.

[7]  W. Harding,et al.  Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. , 2010, Bioorganic & medicinal chemistry letters.

[8]  Wei Qiao,et al.  Synthesis, biological evaluation and molecular modeling of oxoisoaporphine and oxoaporphine derivatives as new dual inhibitors of acetylcholinesterase/butyrylcholinesterase. , 2009, European journal of medicinal chemistry.

[9]  W. Harding,et al.  Microwave-Assisted Direct Biaryl Coupling: First Application to the Synthesis of Aporphines. , 2009, Tetrahedron letters.

[10]  W. Harding,et al.  (+/-)-Nantenine analogs as antagonists at human 5-HT(2A) receptors: C1 and flexible congeners. , 2009, Bioorganic & medicinal chemistry letters.

[11]  F. Stocchi.  Use of apomorphine in Parkinson’s disease , 2008, Neurological Sciences.

[12]  Xuechu Zhen,et al.  N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. , 2008, Bioorganic & medicinal chemistry.

[13]  Jennifer R. Selken,et al.  α1-Adrenergic receptors mediate the locomotor response to systemic administration of (±)-3,4-methylenedioxymethamphetamine (MDMA) in rats , 2007, Pharmacology Biochemistry and Behavior.

[14]  R. Baldessarini,et al.  Advances in development of dopaminergic aporphinoids. , 2007, Journal of medicinal chemistry.

[15]  J. Docherty,et al.  Effects of MDMA, MDA and MDEA on blood pressure, heart rate, locomotor activity and body temperature in the rat involve α‐adrenoceptors , 2006, British journal of pharmacology.

[16]  B. Cassels,et al.  8-NH2-Boldine, an Antagonist of α1A and α1B Adrenoceptors without Affinity for the α1D Subtype: Structural Requirements for Aporphines at α1-Adrenoceptor Subtypes , 2005 .

[17]  Steven G Potkin,et al.  Targeting acetylcholinesterase and butyrylcholinesterase in dementia. , 2005, The international journal of neuropsychopharmacology.

[18]  D. Goldstein,et al.  Carvedilol reverses hyperthermia and attenuates rhabdomyolysis induced by 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) in an animal model* , 2005, Critical care medicine.

[19]  T. Ullrich,et al.  Role of the serotonin 5-HT2A receptor in the hyperlocomotive and hyperthermic effects of (+)-3,4-methylenedioxymethamphetamine , 2005, Psychopharmacology.

[20]  C. Bailly,et al.  Cytotoxic and antitumor potentialities of aporphinoid alkaloids. , 2005, Current medicinal chemistry. Anti-cancer agents.

[21]  T. Ullrich,et al.  Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice , 2004, Psychopharmacology.

[22]  Y. Ohizumi,et al.  (±)-Domesticine, a novel and selective α1D-adrenoceptor antagonist in animal tissues and human α1-adrenoceptors , 2002 .

[23]  M. Michel,et al.  Affinity profile at α1- and α2-adrenoceptor subtypes and in vitro cardiovascular actions of (+)-boldine , 2002 .

[24]  Y. Ohizumi,et al.  Structure-activity relationship on (+/-)-nantenine derivatives in antiserotonergic activities in rat aorta. , 2002, Canadian journal of physiology and pharmacology.

[25]  Y. Ohizumi,et al.  Structure-activity relationship studies with (+/-)-nantenine derivatives for alpha1-adrenoceptor antagonist activity. , 2002, European journal of pharmacology.

[26]  F. Vollenweider,et al.  Psychological and Physiological Effects of MDMA (“Ecstasy”) after Pretreatment with the 5-HT2 Antagonist Ketanserin in Healthy Humans , 2000, Neuropsychopharmacology.

[27]  J. P. Long,et al.  A-ring ortho-disubstituted aporphine derivatives as potential agonists or antagonists at serotonergic 5-HT1A receptors. , 1995, Journal of Medicinal Chemistry.

[28]  J. P. Long,et al.  Preparation and pharmacological evaluation of enantiomers of certain nonoxygenated aporphines: (+)- and (-)-aporphine and (+)- and (-)-10-methylaporphine. , 1993, Journal of medicinal chemistry.

[29]  T. Yokomatsu,et al.  N-demethylation of dibenz[b,f]azonines with mercuric acetate. , 1977 .

[30]  J. P. Long,et al.  Enantiomers of 11-hydroxy-10-methylaporphine having opposing pharmacological effects at 5-HT1A receptors. , 1991, Chirality.